Why Mineralys Therapeutics, Inc.’s (MLYS) Stock Is Up 5.59%
As of Wednesday, June 17, Mineralys Therapeutics, Inc.’s MLYS share price has surged by 5.59%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Commentary & Analysis
Why Mineralys Therapeutics, Inc.’s (MLYS) Stock Is Down 16.15%
As of Wednesday, June 03, Mineralys Therapeutics, Inc.’s MLYS share price has dipped by 16.15%, which has investors questioning if this is right time to buy.Michael Rose
Why Mineralys Therapeutics, Inc.’s (MLYS) Stock Is Down 15.37%
As of Wednesday, June 03, Mineralys Therapeutics, Inc.’s MLYS share price has dipped by 15.37%, which has investors questioning if this is right time to buy.Tudor Pop
Why Mineralys Therapeutics, Inc.’s (MLYS) Stock Is Down 5.40%
As of Tuesday, June 02, Mineralys Therapeutics, Inc.’s MLYS share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Michael Rose
Why Mineralys Therapeutics, Inc.’s (MLYS) Stock Is Up 6.84%
As of Wednesday, May 20, Mineralys Therapeutics, Inc.’s MLYS share price has surged by 6.84%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | MLYS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,249.8 | $252.6 | 55% |
|
| Shares Out (Mil) | 82.8 | 52.3 | 59% |
|
| Institutional Ownership | 99.3% | 92.1% | 87% |
|
| Float (Mil) | 66.2 | 40.2 | 54% |
|
| Beta | 0.48 | 0.95 | 27% |
|
| Avg Daily Volume (000s) | 608 | 455 | 62% |
|
| Price Change (52-week) |
76.1% | 52.9% | 88% |
|
| Growth | MLYS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (114.6%) | (9.9%) | 1% |
|
| EPS (5yr) | (25.3%) | 16.0% | 10 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 23.7% | (15.6%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.535) | ($2.239) | ($2.096) | |
| Month Ago EPS | ($0.535) | ($2.239) | ($2.096) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 0 | 2 | |
| Three Months Ago EPS | ($0.465) | ($2.090) | ($1.808) | |
| Year/Year Chg | 12.6% | (2.1%) | (49.0%) | |
| Financials | MLYS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($152) | ($43) | 8% |
|
| EPS (TTM) | ($2.022) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($136) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($52) | $5 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,791 | $180 | 48% |
|
| Valuation | MLYS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.30 | 2.56 | 68% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MLYS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (30.1%) | (49.8%) | 17% |
|
| ROE | (31.0%) | (55.5%) | 20% |
|
| Liabilities to Assets | 2.3% | 30.3% | 1% |
|
| F-Score | 3 | 3 | 19% |
|
Mineralys Therapeutics, Inc. did not pass any screens on 7/31/2026.
